Maria Roussou Selected Research

Waldenstrom Macroglobulinemia (Macroglobulinemia)

1/2019	Elevated vWF Antigen Serum Levels Are Associated With Poor Prognosis, and Decreased Circulating ADAMTS-13 Antigen Levels Are Associated With Increased IgM Levels and Features of WM but not Increased vWF Levels in Patients With Symptomatic WM.
12/2018	Detection of MYD88 and CXCR4 mutations in cell-free DNA of patients with IgM monoclonal gammopathies.
1/2018	Circulating Soluble Receptor Activator of Nuclear Factor Kappa B Ligand and C-C Motif Ligand 3 Correlate With Survival in Patients With Waldenström Macroglobulinemia.
1/2017	Phase 2 study of ofatumumab, fludarabine and cyclophosphamide in relapsed/refractory Waldenström's macroglobulinemia.
9/2015	Dexamethasone, rituximab, and cyclophosphamide as primary treatment of Waldenström macroglobulinemia: final analysis of a phase 2 study.
3/2009	Rituximab-based treatments in Waldenström's macroglobulinemia.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Maria Roussou Research Topics

Disease

32	Multiple Myeloma 03/2024 - 04/2007
15	Immunoglobulin Light-chain Amyloidosis 11/2023 - 10/2007
6	Waldenstrom Macroglobulinemia (Macroglobulinemia) 01/2019 - 03/2009
5	Residual Neoplasm 12/2021 - 10/2019
5	Paraproteinemias (Monoclonal Gammopathy) 01/2021 - 10/2011
5	Neoplasms (Cancer) 01/2019 - 04/2009
4	Renal Insufficiency (Renal Failure) 05/2016 - 04/2007
3	Infections 09/2023 - 10/2019
3	COVID-19 09/2023 - 01/2021
3	Amyloidosis 10/2019 - 06/2012
3	Chromosome Aberrations (Chromosome Abnormalities) 01/2017 - 07/2012
2	Disease Progression 01/2021 - 12/2018
2	Peripheral Nervous System Diseases (PNS Diseases) 10/2019 - 10/2018
2	Cardiovascular Diseases (Cardiovascular Disease) 02/2017 - 01/2016
1	Hemorrhage 02/2024
1	Thrombosis (Thrombus) 02/2024
1	Pain (Aches) 09/2023
1	Plasma Cell Neoplasms 01/2021
1	Lymphopenia (Lymphocytopenia) 01/2021
1	Kidney Diseases (Kidney Disease) 10/2020
1	POEMS Syndrome (Syndrome, POEMS) 01/2020
1	Hypercalcemia (Milk Alkali Syndrome) 01/2020
1	Constipation 10/2019
1	Exanthema (Rash) 10/2019
1	Diarrhea 10/2018
1	Thrombocytopenia (Thrombopenia) 10/2018
1	Leishmaniasis 01/2018
1	Proteinuria 01/2018
1	Monoclonal Gammopathy of Undetermined Significance 01/2018
1	Osteonecrosis (Kienbock's Disease) 10/2017
1	Carcinogenesis 07/2017
1	Wounds and Injuries (Trauma) 01/2016

Drug/Important Bio-Agent (IBA)

16	Dexamethasone (Maxidex)FDA LinkGeneric 01/2024 - 04/2007
15	Lenalidomide (CC 5013)FDA Link 03/2024 - 07/2010
15	Bortezomib (Velcade)FDA Link 12/2021 - 04/2007
6	daratumumabIBA 11/2023 - 01/2018
6	Cyclophosphamide (Cytoxan)FDA LinkGeneric 12/2021 - 04/2007
5	Monoclonal AntibodiesIBA 09/2023 - 03/2009
4	belantamab mafodotinIBA 01/2024 - 01/2021
4	carfilzomibIBA 01/2021 - 02/2017
4	Immunoglobulin M (IgM)IBA 01/2020 - 01/2018
3	Neutralizing AntibodiesIBA 09/2023 - 01/2021
3	Nerve Growth Factor (NGF)IBA 12/2021 - 01/2021
3	Immunoglobulins (Immunoglobulin)IBA 01/2021 - 06/2020
3	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 01/2020 - 08/2010
3	Biomarkers (Surrogate Marker)IBA 01/2018 - 01/2016
2	CreatinineIBA 02/2024 - 05/2008
2	VaccinesIBA 09/2023 - 01/2021
2	bis(3- bis(4- chlorophenyl)methyl- 4- dimethylaminophenyl)amineIBA 07/2023 - 08/2022
2	BNT162 VaccineIBA 08/2022 - 01/2021
2	Diphosphonates (Bisphosphonates)IBA 01/2020 - 01/2019
2	Cell-Free Nucleic AcidsIBA 01/2020 - 12/2018
2	Immunomodulating AgentsIBA 12/2019 - 01/2018
2	Melphalan (Alkeran)FDA LinkGeneric 10/2019 - 10/2007
2	Chemokine CCL3IBA 01/2018 - 02/2011
2	LigandsIBA 01/2018 - 02/2011
2	Proteins (Proteins, Gene)FDA Link 01/2016 - 07/2012
2	Rituximab (Mabthera)FDA Link 09/2015 - 03/2009
2	Proteasome InhibitorsIBA 05/2008 - 10/2007
2	Thalidomide (Thalomid)FDA Link 04/2007 - 04/2007
1	AlbuminsIBA 02/2024
1	cilgavimab and tixagevimab drug combinationIBA 09/2023
1	AntibodiesIBA 09/2023
1	Messenger RNA (mRNA)IBA 09/2023
1	tixagevimabIBA 09/2023
1	cilgavimabIBA 09/2023
1	B-Cell Maturation AntigenIBA 07/2023
1	molnupiravirIBA 01/2023
1	Antiviral Agents (Antivirals)IBA 01/2023
1	Ritonavir (Norvir)FDA Link 01/2023
1	nirmatrelvirIBA 01/2023
1	ATP dependent 26S protease (26S proteasome)IBA 01/2021
1	ChAdOx1 nCoV-19IBA 01/2021
1	Urokinase Plasminogen Activator ReceptorsIBA 10/2020
1	Immunoglobulin Light Chains (Immunoglobulin Light Chain)IBA 06/2020
1	pomalidomideIBA 12/2019
1	Drug CombinationsIBA 10/2019
1	Dihydrotachysterol (AT 10)IBA 10/2019
1	ParaproteinsIBA 01/2019
1	DNA (Deoxyribonucleic Acid)IBA 12/2018
1	Growth Differentiation Factor 15IBA 01/2018
1	RANK LigandIBA 01/2018
1	Zoledronic Acid (Zometa)FDA Link 10/2017
1	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 07/2017
1	Platelet-Derived Growth FactorIBA 07/2017
1	Platelet-Derived Growth Factor Receptors (Platelet-Derived Growth Factor Receptor)IBA 07/2017
1	fludarabineIBA 01/2017
1	Immunoglobulin FragmentsIBA 01/2017
1	ofatumumab FDA Link 01/2017
1	Amyloid (Amyloid Fibrils)IBA 01/2016
1	Cystatin CIBA 01/2016
1	von Willebrand FactorIBA 01/2016
1	Metalloproteases (Metalloproteinases)IBA 01/2016
1	AntigensIBA 01/2016
1	Lipocalin-2IBA 01/2016

Therapy/Procedure

17	Therapeutics 03/2024 - 10/2011
2	Stem Cell Transplantation 11/2010 - 10/2007
1	Drug Tapering 10/2019
1	Salvage Therapy 12/2018
1	Aftercare (After-Treatment) 01/2017